Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3731579 in Healthy Male Subjects
NCT06429137Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3731579 (9 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent Adverse Events at 96 hours. Started Jul 2024; status: completed.
02
Drugs
BI 3731579
Beyond the preview
Go deeper on NCT06429137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429137.